金币
UID725485
帖子
主题
积分3869
注册时间2021-7-13
最后登录1970-1-1
听众
性别保密
|
发表于 2022-3-15 20:07:27
|
显示全部楼层
本帖最后由 笑看人生ha1 于 2022-3-15 20:35 编辑
临床评价计划在MDR附录十四的A部分中提到 ,另还需制订临床开发计划。以下是MDR对临床评价计划的要求:
(a) establish and update a clinical evaluation plan, which shall include at least:
— an identification of the general safety and performance requirements that require support from relevant
clinical data;
— a specification of the intended purpose of the device;
— a clear specification of intended target groups with clear indications and contra-indications;
— a detailed description of intended clinical benefits to patients with relevant and specified clinical outcome
parameters;
— a specification of methods to be used for examination of qualitative and quantitative aspects of clinical
safety with clear reference to the determination of residual risks and side-effects;
— an indicative list and specification of parameters to be used to determine, based on the state of the art in
medicine, the acceptability of the benefit-risk ratio for the various indications and for the intended purpose
or purposes of the device;
— an indication how benefit-risk issues relating to specific components such as use of pharmaceutical, nonviable animal or human tissues, are to be addressed; and
— a clinical development plan indicating progression from exploratory investigations, such as first-in-man
studies, feasibility and pilot studies, to confirmatory investigations, such as pivotal clinical investigations,
and a PMCF as referred to in Part B of this Annex with an indication of milestones and a description of
potential acceptance criteria;
(a)建立并更新临床评价计划,该计划至少应包括:
-识别需要相关临床数据支持的通用安全和性能要求;
-器械的预期目的规范说明;
-明确规定预期目标人群以及明确适应证和禁忌证;
-对具有相关和具体的临床结果参数的患者预期临床受益的详细描述;
-临床安全的定性和定量方面的检查方法的规范,并明确参考剩余风险和副作用的确定;
-用于根据医学的最新技术水平确定器械各种适应证和预期目的的受益风险比的可接受性所使用的参数的提示性清单和规范;
-如何解决特定方面(如药物、非活性动物或人体组织的使用)相关的受益风险问题的提示;
-用于提示从探索性研究(如首次人体研究、可行性和试点研究)到验证性研究(如关键的临床调查)进展过程的临床开发计划,以及本附录第B部分所述的PMCF,此PMCF需列出时间表并描述潜在接收标准。 |
|